Question 79

Amiodarone and amantadine are considered a risk.

The Institute for Safe Medication Practices (ISMP) identifies amiodarone and amantadine as a pair that poses a risk due to their similar names, which can lead to medication errors.

A) Amiodarone and amantadine

This option is correct as it directly aligns with the ISMP's identification of confused drug names. The similarity in their names can easily lead to miscommunication and errors in prescribing and dispensing these medications.

B) Atorvastatin and simvastatin

While atorvastatin and simvastatin are both statins used for lowering cholesterol, they are not noted by the ISMP as a pair that is particularly confused. Their distinct prefixes and suffixes help differentiate them, reducing the risk of confusion.

C) Furosemide and famotidine

Furosemide, a diuretic, and famotidine, an H2 antagonist, do not share a similarity in naming that would lead to confusion according to the ISMP. Their differing uses and phonetic structures lessen the likelihood of errors between these two drugs.

D) Cephalexin and ciprofloxacin

Cephalexin and ciprofloxacin, although both antibiotics, are not cited by the ISMP as a confused pair. The differences in their names, as well as their classes and indications, contribute to a clearer distinction when prescribing and administering these medications.

Conclusion

Amiodarone and amantadine are identified as a risky pair due to their similar names, which can easily lead to medication errors. In contrast, the other options, while they may involve medications that are similar in function or classification, do not have the same level of confusion as noted by the ISMP. Therefore, option A stands out as the correct answer.